Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 19/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456326 | 1.00 | CYP11B2 (0.61) | CYP11B2CMA1CYP17A1CYP1A2CYP19A1 | |
| SCHEMBL25584225 | 0.88 | CYP11B2 (0.58) | CYP11B2CYP17A1CYP1A2CYP19A1CYP11B1 | |
| SCHEMBL17456274 | 0.87 | CYP11B2 (0.67) | CYP11B2CYP17A1CYP1A2CYP19A1CYP11B1 | |
| SCHEMBL17456288 | 0.81 | CYP11B2 (0.56) | CYP11B2 | |
| SCHEMBL17456269 | 0.79 | CYP11B2 (0.60) | CYP11B2CYP11B1 | |
| SCHEMBL17456265 | 0.78 | CYP11B2 (0.58) | CYP11B2 | |
| SCHEMBL25584680 | 0.77 | CYP11B2 (0.50) | CYP11B2CYP11B1 | |
| SCHEMBL17456310 | 0.77 | CYP11B2 (0.60) | CYP11B2 | |
| SCHEMBL17456319 | 0.77 | CYP11B2 (0.64) | CYP11B2CYP11B1 | |
| SCHEMBL25584182 | 0.77 | CYP11B2 (0.64) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263157-B2 | Aldosterone synthase inhibitors for treating chronic kidney disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-20250049763-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | BOEHRINGER INGELHEIM INT (DE) | 2025-02-13 | — | — | US | disclosed |
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-3172212-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-9334285-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-20160024105-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024105-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | CYP11B2 3/4885CMA1 179/4885CYP17A1 4/4885 |
| US-20250049763-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | SLC5A2, SLC5A1, REN | CYP11B2 10/4885CMA1 1259/4885CYP17A1 31/4885 |
| US-20230181538-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | SLC5A2, SLC5A1, REN | CYP11B2 10/4885CMA1 1410/4885CYP17A1 29/4885 |
| US-12263157-B2 | Aldosterone synthase inhibitors for treating chronic kidney disease | SLC5A1, SLC5A2, REN | CYP11B2 12/4885CMA1 1033/4885CYP17A1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.